B+
Bull case
25%
Probability
Target price
$10.00
+90.5% vs current
ALGS
Aligos TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$5.80
+10.5% vs current
B-
Bear case
30%
Probability
Target price
$3.00
-42.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-09
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+63.8
Score
AI commentary
This T+3 follow-up confirms the May 7, 2026 company earnings release and updates the thesis only modestly. The tone improved at the margin because management extended expected runway into Q4 2026 and highlighted the $25 million Amoytop upfront, but the 10-Q still carries going-concern language and the decisive value event remains a 2027 clinical readout. Market reaction was not decisive: the packet anchor was $6.03 on May 7, 2026, and the latest quote checked was about $6.44 on May 9, 2026 UTC, suggesting only a modest post-print bounce. No trustworthy delayed analyst revision signal was confirmed, and peer benchmarking remains tentative because the cleanest public HBV peers are operating comparators rather than close same-scale valuation comps, so this remains a cautious monitoring setup rather than a thesis upgrade.
RankAlpha Sentiment Codex - 2026-05-09
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-09-15eventSecond B-SUPREME interim analysis in 2H 2026High impact
Management said the Phase 2 B-SUPREME study remains ongoing, the first interim analysis cleared futility, the DSMB recommended increasing the HBeAg- sample size to 100 from 74, and the second protocol-defined interim analysis is expected in the second half of 2026 [#8-K-2026-05-07]. A clean update would help offset financing pressure, but the sample-size increase also shows the study needed more power.
2026-10-01catalystRunway and financing watch moved out but not removedHigh impact
The May 7 earnings release said cash, cash equivalents and investments were $54.9 million at March 31, 2026 and are expected to fund planned operations into the fourth quarter of 2026, inclusive of the expected $25 million Amoytop upfront, while the 10-Q still says recurring losses and negative cash flows raise substantial doubt about continuing as a going concern [#8-K-2026-05-07] [#10-Q-2026-05-07]. That modestly improves near-term flexibility versus the prior Q3 runway framing, but it still leaves a likely financing or partnering decision before the 2027 clinical readout.
2027-06-30catalyst2027 B-SUPREME topline remains the main value driverHigh impact
Aligos reaffirmed that topline data for both HBeAg- and HBeAg+ B-SUPREME cohorts are expected in 2027, keeping the HBV program as the core long-duration upside case [#8-K-2026-05-07]. The setup remains binary because the company still appears likely to need capital before that readout.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-09 • Updated nightlySource: Internal modelMethodology